Bladder cancer

Topic: --NEW--It’s getting personalised: 1st-line treatment for mUCa

Earn accreditation points

Finish 5 cases, answer 10 questions and Earn 1 credit.

This topic consists of 5 cases

Disease Area: Bladder cancer
Background: Standard 1st-line treatment for mUCa patients has been platinum-based chemotherapy for many years. The advent of immunotherapy broadens the treatment landscape, especially for cisplatin-ineligible patients, and paves the way for more personalised medicine
Educational Objective: Appreciate the different treatment options for cisplatin eligible and ineligible patients. Gain insight on other factors that have an impact on treatment decision, e.g. (time since) previous systemic therapy in the M0 setting; ECOG PS and PD-L1 status
Specialty: Medical oncology, urology, clinical oncology, (radiation oncology)
Target Audience: CME: intermediate-advanced | Residents: senior
Latest update: August 2019
Back to topic overview